PURPOSE: Patients with Ewing sarcoma (ES) with metastases and those who relapse fare poorly and receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES. PATIENTS AND METHODS: Patients with sarcoma 10 to 18 years old were enrolled in two dose escalation cohorts (20 and 30 mg/Kg intravenously every 4 weeks) in the phase 1 portion of the study. Patients with ES 10 years old or older were enrolled in the phase 2 portion of the study. The primary phase 2 objective was objective response rate (ORR). RESULTS: Thirty-one patients with ES (n = 16), osteosarcoma (n = 11), or other sarcomas (n = 4) were enrolled in the phase 1 portion of the study. Dose escalation proceeded to 30 mg/kg every 4 weeks with no dose-limiting toxicity identified. In the phase 2 portion of the study, 107 patients with ES received figitumumab at 30 mg/kg every 4 weeks for a median of 2 cycles (range, 1 to 16). Sixty three percent of phase 2 patients had received at least three prior treatment regimens. Of 106 evaluable patients, 15 had a partial response (ORR, 14.2%) and 25 had stable disease. Median overall survival was 8.9 months. Importantly, patients with a pretreatment circulating free insulin-like growth factor (IGF) -1 lower than 0.65 ng/mL (n = 14) had a median OS of 3.6 months, whereas those with a baseline free IGF-1 ≥ 0.65 ng/mL (n = 84) had a median OS of 10.4 months (P < .001). CONCLUSION: Figitumumab had modest activity as single agent in advanced ES. A strong association between pretreatment serum IGF-1 and survival benefit was identified.
PURPOSE:Patients with Ewing sarcoma (ES) with metastases and those who relapse fare poorly and receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES. PATIENTS AND METHODS: Patients with sarcoma 10 to 18 years old were enrolled in two dose escalation cohorts (20 and 30 mg/Kg intravenously every 4 weeks) in the phase 1 portion of the study. Patients with ES 10 years old or older were enrolled in the phase 2 portion of the study. The primary phase 2 objective was objective response rate (ORR). RESULTS: Thirty-one patients with ES (n = 16), osteosarcoma (n = 11), or other sarcomas (n = 4) were enrolled in the phase 1 portion of the study. Dose escalation proceeded to 30 mg/kg every 4 weeks with no dose-limiting toxicity identified. In the phase 2 portion of the study, 107 patients with ES received figitumumab at 30 mg/kg every 4 weeks for a median of 2 cycles (range, 1 to 16). Sixty three percent of phase 2 patients had received at least three prior treatment regimens. Of 106 evaluable patients, 15 had a partial response (ORR, 14.2%) and 25 had stable disease. Median overall survival was 8.9 months. Importantly, patients with a pretreatment circulating free insulin-like growth factor (IGF) -1 lower than 0.65 ng/mL (n = 14) had a median OS of 3.6 months, whereas those with a baseline free IGF-1 ≥ 0.65 ng/mL (n = 84) had a median OS of 10.4 months (P < .001). CONCLUSION:Figitumumab had modest activity as single agent in advanced ES. A strong association between pretreatment serum IGF-1 and survival benefit was identified.
Authors: Jacqueline M Major; Gail A Laughlin; Donna Kritz-Silverstein; Deborah L Wingard; Elizabeth Barrett-Connor Journal: J Clin Endocrinol Metab Date: 2010-01-15 Impact factor: 5.958
Authors: Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton Journal: Cancer Res Date: 2009-09-29 Impact factor: 12.701
Authors: David Olmos; Sophie Postel-Vinay; L Rhoda Molife; Scott H Okuno; Scott M Schuetze; M Luisa Paccagnella; Gretchen N Batzel; Donghua Yin; Kathryn Pritchard-Jones; Ian Judson; Francis P Worden; Antonio Gualberto; Michelle Scurr; Johann S de Bono; Paul Haluska Journal: Lancet Oncol Date: 2009-12-23 Impact factor: 41.316
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Lillian M Guenther; Neekesh V Dharia; Linda Ross; Amy Conway; Amanda L Robichaud; Jerrel L Catlett; Caroline S Wechsler; Elizabeth S Frank; Amy Goodale; Alanna J Church; Yuen-Yi Tseng; Rajarshi Guha; Crystal G McKnight; Katherine A Janeway; Jesse S Boehm; Jaume Mora; Mindy I Davis; Gabriela Alexe; Federica Piccioni; Kimberly Stegmaier Journal: Clin Cancer Res Date: 2018-11-05 Impact factor: 12.531
Authors: Gregory M Hayes; Belinda Cairns; Zoia Levashova; Lawrence Chinn; Myra Perez; Jan-Willem Theunissen; Sindy Liao-Chan; Abel Bermudez; Mark R Flory; Karl J Schweighofer; Edward H van der Horst Journal: Am J Transl Res Date: 2015-06-15 Impact factor: 4.060
Authors: Michael J Wagner; Vancheswaran Gopalakrishnan; Vinod Ravi; J Andrew Livingston; Anthony P Conley; Dejka Araujo; Neeta Somaiah; Maria A Zarzour; Ravin Ratan; Wei-Lien Wang; Shreyaskumar R Patel; Alexander Lazar; Joseph A Ludwig; Robert S Benjamin Journal: Oncologist Date: 2017-07-14
Authors: Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal Journal: Nat Rev Clin Oncol Date: 2017-05-16 Impact factor: 66.675
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Mukund Patel; Nicholas C Gomez; Andrew W McFadden; Billie M Moats-Staats; Sam Wu; Andres Rojas; Travis Sapp; Jeremy M Simon; Scott V Smith; Kathleen Kaiser-Rogers; Ian J Davis Journal: Mol Cancer Res Date: 2014-07-03 Impact factor: 5.852